Talía Malagón

Talía Malagón

Auto-generated profile, based on publicly available information

Talía Malagón

Division of Cancer Epidemiology, Gerald Bronfman Department of Oncology, McGill University, Montreal, Canada

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 May 2024 in Nature Reviews Clinical Oncology
Verified
Journal Article
Closed access
PDF file
TMTalía Malagón
Talía Malagón
EFEduardo Franco
Eduardo Franco
RTRomina Tejada
Romina Tejada
SVSalvatore Vaccarella
Salvatore Vaccarella

3 December 2021 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
TMTalía Malagón
Talía Malagón
JYJean H. E. Yong
Jean H. E. Yong
PTParker Tope
Parker Tope
WMWilson H. Miller
Wilson H. Miller
EFEduardo Franco
Eduardo Franco
MCMcGill Task Force on the Impact of COVID‐19 on Cancer Control and Care
McGill Task Force on the Impact of COVID‐19 on Cancer Control and Care
The COVID‐19 pandemic has affected cancer care worldwide. This study aimed to estimate the long‐term impacts of cancer care disruptions on cancer mortality in Canada using a microsimulation model. The model simulates cancer incidence and survival using cancer incidence, stage at diagnosis and survival data from the Canadian Cancer Registry. We modeled reported declines in cancer diagnoses and treatments recorded in provincial administrative datasets in March 2020 to June 2021. Based on the literature, we assumed that diagnostic and treatment delays lead to a 6% higher rate of cancer death per 4‐week delay. After June 2021, we assessed scenarios where cancer treatment capacity returned to prepandemic levels, or to 10% higher or lower than prepandemic levels. Results are the median predictions of 10 stochastic simulations. The model predicts that cancer care disruptions during the COVID‐19 pandemic could lead to 21 247 (2.0%) more cancer deaths in Canada in 2020 to 2030, assuming treatment capacity is recovered to 2019 prepandemic levels in 2021. This represents 355 172 life years lost expected due to pandemic‐related diagnostic and treatment delays. The largest number of expected excess cancer deaths was predicted for breast, lung and colorectal cancers, and in the provinces of Ontario, Québec and British Columbia. Diagnostic and treatment capacity in 2021 onward highly influenced the number of cancer deaths over the next decade. Cancer care disruptions during the COVID‐19 pandemic could lead to significant life loss; however, most of these could be mitigated by increasing diagnostic and treatment capacity in the short‐term to address the service backlog.

1 December 2018 in The Lancet Oncology
Verified
Journal Article
Closed access
TMTalía Malagón
Talía Malagón
SKShalini Kulasingam
Shalini Kulasingam
MMMarie-Hélène Mayrand
Marie-Hélène Mayrand
GOGina Ogilvie
Gina Ogilvie
LSLeah Smith
Leah Smith
EFEduardo Franco
Eduardo Franco

9 September 2017 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
TMTalía Malagón
Talía Malagón
ABAnn N Burchell
Ann N Burchell
MEMariam El-Zein
Mariam El-Zein
JGJulie Guénoun
Julie Guénoun
PTPierre-Paul Tellier
Pierre-Paul Tellier
ECEmilie Comète
Emilie Comète
Detection of human papillomavirus (HPV) DNA in genital samples may not always represent true infections but may be depositions from infected sexual partners. We examined whether sexual risk factors and a biomarker (Y chromosome DNA) were associated with genital HPV partner concordance and estimated the fraction of HPV detections potentially attributable to partner deposition. The HITCH study enrolled young women attending a university or college in Montréal, Canada, and their male partners, from 2005 to 2010. We tested baseline genital samples for Y chromosome DNA and HPV DNA using polymerase chain reaction. Type-specific HPV concordance was 42.4% in partnerships where at least one partner was HPV DNA positive. Y chromosome DNA predicted type-specific HPV concordance in univariate analyses, but in multivariable models the independent predictors of concordance were days since last vaginal sex (26.5% higher concordance 0–1 vs 8–14 days after last vaginal sex) and condom use (22.6% higher concordance in never vs always users). We estimated that 14.1% (95% confidence interval [CI], 6.3–21.9%) of HPV DNA detections in genital samples were attributable to vaginal sex in the past week. A substantial proportion of HPV DNA detections may be depositions due to recent unprotected vaginal sex.

28 November 2021 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
PDF file
TMTalía Malagón
Talía Malagón
AMAaron MacCosham
Aaron MacCosham
ABAnn N Burchell
Ann N Burchell
MEMariam El-Zein
Mariam El-Zein
PTPierre Paul Tellier
Pierre Paul Tellier
ECEmilie Comète
Emilie Comète
Background: Infections with human papillomaviruses (HPVs) may enter a latent state, and eventually become reactivated following loss of immune control. It is unclear what proportion of incident HPV detections are reactivations of previous latent infections vs new transmissions. Methods: The HPV Infection and Transmission among Couples through Heterosexual activity (HITCH) cohort study prospectively followed young newly formed heterosexual partners recruited between 2005 and 2011 in Montréal, Canada. We calculated the fraction of incident HPV detections nonattributable to sexual transmission risk factors with a Bayesian Markov model. Results are the median (2.5th-97.5th percentiles) of the estimated posterior distribution. Results: A total of 544 type-specific incident HPV detection events occurred in 849 participants; 33% of incident HPV detections occurred in participants whose HITCH partners were negative for that HPV type and who reported no other sex partners over follow-up. We estimate that 43% (38%–48%) of all incident HPV detections in this population were not attributable to recent sexual transmission and might be potentially reactivation of latent infections. Conclusions: A positive HPV test result in many cases may be a reactivated past infection, rather than a new infection from recent sexual behaviors or partner infidelity. The potential for reactivation of latent infections in previously HPV-negative women should be considered in the context of cervical cancer screening.

1 November 2019 in Gynecologic Oncology
Verified
Journal Article
Closed access
TMTalía Malagón
Talía Malagón
KLKarolina Louvanto
Karolina Louvanto
ARAgnihotram V. Ramanakumar
Agnihotram V. Ramanakumar
AKAnita Koushik
Anita Koushik
FCFrançois Coutlée
François Coutlée
EFEduardo L. Franco
Eduardo L. Franco